BridgeMD
New treatment option for Acute Lymphoblastic Leukemia, Pediatric
Official title Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea
ClinicalTrials.gov ID: NCT06257394
What this study is testing
What is Dasatinib(Sprycel) arm?
Dasatinib(Sprycel) arm is an investigational medicine, given as an injection into a muscle, being studied as a potential treatment for acute lymphoblastic leukemia, pediatric.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Very high-risk acute lymphoblastic leukemia
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 1 to 19
You may be able to join if
- Pediatric patients diagnosed with ALL between the ages of 1 and 19 years at the time of diagnosis who meet one or more of the following conditions:
- Philadelphia chromosome-positive t(9;22)(q34;q11) or
- Patients with failed remission who had blast \> 5% on bone marrow test after initial remission induction therapy or
- Hypodiploidy (Number of chromosomes \< 44 (less than 44)) or
- E2A-HLF(Hepatic Leukemia Factor) translocation-positive or
You likely can't join if
- Participants with contraindications to medications
- When the study participant or their legal representative withdraws consent
- Pregnant or lactating women (patients of child-bearing potential require adequate contraception during the study period)
- Participants who are medically unsuitable to participate in this study at the discretion of the investigator Participants participating in other...
See the full eligibility criteria
- Pediatric patients diagnosed with ALL between the ages of 1 and 19 years at the time of diagnosis who meet one or more of the following conditions:
- Philadelphia chromosome-positive t(9;22)(q34;q11) or
- Patients with failed remission who had blast \> 5% on bone marrow test after initial remission induction therapy or
- Hypodiploidy (Number of chromosomes \< 44 (less than 44)) or
- E2A-HLF(Hepatic Leukemia Factor) translocation-positive or
- When the prognosis is judged to be poor according to NGS-MRD results among high-risk ALL patients (i) In B-ALL, the NGS-MRD(Next Generation Sequencing-Minimal Residual Disease) after consolidation therapy is 0.01% or...
- Participants with contraindications to medications
- When the study participant or their legal representative withdraws consent
- Pregnant or lactating women (patients of child-bearing potential require adequate contraception during the study period)
- Participants who are medically unsuitable to participate in this study at the discretion of the investigator Participants participating in other treatment studies other than this protocol
The study team makes the final eligibility decision.
Where it's taking place
- Seoul, South Korea
- Yangsan, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 1 year to 19 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Seoul, South Korea; Yangsan, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.